Home  »  Business   »  Aridis Pharmaceuticals Inc.’s Stock Price So...

Aridis Pharmaceuticals Inc.’s Stock Price Soared Recently, But There Might Be Trouble Ahead

Aridis Pharmaceuticals Inc. (NASDAQ:ARDS) traded at $0.84 at close of the session on Tuesday, 01/24/23, made a downward move of -28.21% on its previous day’s price.

Looking at the stock we see that its previous close was $1.17 and the beta (5Y monthly) reads 1.40 with the day’s price range being $0.5722 – $1.3398. In terms of its 52-week price range, ARDS has a high of $2.94 and a low of $0.68. The company’s stock has lost about -18.45% over that past 30 days.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Aridis Pharmaceuticals Inc. has a market cap of $18.93 million and is expected to release its quarterly earnings report on Mar 29, 2023 – Apr 03, 2023. Estimates by analysts give the company expected earnings per share (EPS) of -$0.17, with the EPS growth for the year raised at -$0.78 for 2022 and -$0.88 for next year. These figures represent 79.70% and -12.80% growth in EPS for the two years respectively.

The median projection represents growth squeezing down to 1,350.50% compared to sales growth for the corresponding quarter a year ago. According to analyst consensus estimates figures, the company’s yearly revenue forecast for 2022 is expected to hit $29.53 million, or 1,823.80% up from figures reported last year.

There have been no upward and no downward revisions for the stock’s EPS in last 7 days, something that reflects the nature of company’s price movement in short term. On the other hand, looking at the outlook for the ARDS stock, short term indicators assign the stock an average of Hold, while medium term indicators assign it an average of 100% Sell. Long term indicators on average place the stock in the category of 100% Sell.

Based on estimates by 2 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Aridis Pharmaceuticals Inc. (ARDS) stock as a Hold, while 2 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.

Looking further, we note the current price level is -31.28% off its SMA20 and -19.83% from its 50-day simple moving average. The RSI (14) is pointing at 33.57 while the volatility over the past week is 45.12% and jumps to 23.32% over the past one month. The beta value is 1.21, while the average true range (ATR) is currently pointing at 0.23. The average price target for the stock over the next 12 months is $10.50, with the estimates having a low of $2.00 and a high of $19.00. These price ends are -138.1% and -2161.9% off the current price level respectively, although investors could be excited at the prospect of a -1150.0% if the ARDS share price touches on the median price of $10.50.

Coming back to Aridis Pharmaceuticals Inc. (NASDAQ:ARDS), we note that the average 3-month trading volume was 169.20K, while that of the preceding 10-day period stands at 0.49 million. Current shares outstanding are 17.70 million.

The insiders hold 40.26% of the company’s shares while institutions hold 10.20%. The data shows that short shares as of Oct 13, 2022, stood at 0.21 million at a short ratio of 0.69. This represents a 1.18% short interest in shares outstanding on Oct 13, 2022. Shares short rose in October from the previous month at 0.13 million. Investors should be excited about this stock as its upside potential is great, with current price pushing the stock -28.81% down in year-to-date price movement.

Leave a Comment

Your email address will not be published. Required fields are marked *